Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORAL phase II trial of doravirine + raltegravir switch in virologically suppressed HIV-1 patients
2024-513941-35-00Phase 2Authorised
- Sponsor
- Centre de Recherches et d’Etudes sur les Pathologies Infectieuses et Tropicales
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised trial of doravirine and raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Centre de Recherches et d’Etudes sur les Pathologies Infectieuses et Tropicales. Primary endpoint: Primary virological failure rate by week 48. Planned start Dec 2024; status: authorised.
02
Drugs
doravirineraltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-513941-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513941-35-00.